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Figure 1. Panel A: relapse-free survival (log-rank p5 0.16). Panel B:
cumulative incidence of relapse and non-relapse mortality (log-rank
p5 0.29 and p5 0.98, respectively).
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Donor CMV Serostatus Not
Predictive of Relapse in D-/R-
Pediatric HCT
To the Editor:
Cytomegalovirus (CMV) remains a major cause of
complications in hematopoietic cell transplantation
(HCT). Recipient CMV serostatus remains a predictor
of non-relapse mortality in the ganciclovir era and
seronegative recipients with a seronegative donor
Table 1. Baseline Characteristics of Pediatric HCT Recipients and Associated Hazards of Relapse and Non-relapse Mortality
Characteristics
Overall
n5 170 n (%)
D-/R- Graft
n5 72 n (%)
Other Graft
n5 98 n (%)
Relapse adj.
HR (95% CI)
Non-relapse
Mortality (NRM)
adj. HR (95% CI)
CMV D-/R- - - - - - - 0.90 (0.54-1.50) 0.67 (0.30-1.4)
Male 103 (61) 47 (65) 56 (57)
Diagnosis
ALL 90 (53) 39 (54) 51 (52) 0.68 (0.38-1.23) 0.69 (0.27-1.77)
AML 64 (38) 27 (38) 37 (38)
MDS 16 (9) 6 (8) 10 (10)
Disease stage
Relapse 22 (13) 8 (11) 14 (14.) 4.25 (2.15-8.37) † 1.36 (0.36-5.22)
Others 132 (78) 59 (82) 73 (75)
Unknown 16 (9) 5 (7) 11 (11)
Ethnicity
Caucasian 124 (73) 61 (85) 63 (64.)
Others 43 (25) 11 (15) 32 (33)
Unknown 3 (2) 0 (0) 3 (3)
Donor Type
Related 73 (43) 25 (35) 48 (49) 1.14 (0.65-2.0) 1.08 (0.46-2.56)
Unrelated 97 (57) 47 (65) 50 (51)
Donor Age
0-19 Years 50 (29) 19 (26) 31 (32)
20-39 Years 67 (39) 30 (42) 37 (38)
40-55 Years 48 (28) 21 (29) 27 (28)
55+ 5 (3) 2 (2) 3 (3)
Graft Source
Bone marrow 119 (70) 51 (71) 68 (69) 0.37 (0.22-0.63) * 0.40 (0.17-0.93) *
PBSC 51 (30) 21 (29) 30 (31)
Year of transplantation
1997-2002 110 (65) 47 (65) 63 (64)
After 2002 60 (35) 25 (35) 35 (36)
Female-to-male graft
Yes 56 (33) 22 (31) 34 (35)
No 114 (67) 50 (69) 64 (65)
Conditioning regimen
TBI 136 (80) 60 (83) 76 (78) 1.34 (0.58-3.09) 1.37 (0.37-5.08)
Other 30 (18) 11 (15) 19 (19)
Missing 4 (2) 1 (1) 3 (3)
Acute GVHD
Grade 2-4 150 (88) 66 (92) 84 (86) 0.92 (0.42-2.01) 0.65 (0.20-2.14)
Grade 0-1 20 (12) 6 (8) 14 (14)
*p value < 0.05
†p value < 0.001, all factors in multivariate Cox proportional hazards model have associated hazard ratios as shown in the table.
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recent studies [1,2]. It is currently recommended that
seronegative recipients receive a graft from a seronega-
tive donor whenever possible [3]. We therefore read
with interest the article by Behrendt et al. that demon-
strates that children undergoing primary myeloabla-
tive HCT have an increased risk of relapse in D-/R-
grafts, and that there was no impact of recipient or
donor CMV serostatus on non-relapse mortality [4].
We replicated the analyses with identical inclusion
criteria and methods. In our sample we analyzed 170
children from 0-18 years of age who underwent
primary, myeloablative, non T-cell depleted alloge-
neic HCT at the Fred Hutchinson Cancer Research
Center and Seattle Children’s Hospital from 1997
through 2005. All patients underwent CMV surveil-
lance and received preemptive antiviral therapy with
ganciclovir (or foscarnet if neutropenic); all patients
received low-dose acyclovir for herpes simplex and
varicella zoster virus prophylaxis [5]. Our sample was
different in ethnic makeup and prior conditioning reg-imens (Table 1), but otherwise our populations were
comparable. In contrast to their study, in univariate
analysis we did not find a difference in median re-
lapse-free survival (log-rank test, p5 0.16) when com-
paring D-/R- subjects and other grafts (Figure 1A).
Similarly, in a multivariate Cox proportional hazards
model with similar adjustments, D-/R- transplant re-
cipients were not at higher risk for relapse (HR 0.9,
95% CI 0.54-1.50). There was also no difference in
relapse or non-relapse mortality when comparing
D-/R- and other grafts (Figure 1B).
Our study results are in contrast to the study by
Behrendt et al. Since these data are generated at two
separate centers, many factors could have led to con-
flicting results. These differences could potentially be
explained by the different racial/ethnic make-up of
their cohort (a higher incidence of Hispanics), and
we would be interested if these findings are similar
after adjustment for these characteristics. Differences
in the conditioning regimens (e.g. in the use of etopo-
side) could also be important. Given that they
760 Biol Blood Marrow Transplant 15:757-760, 2009Letters to the Editordescribe an age distribution peak at age 1 [4], a third
possible explanation could be a larger proportion in
their cohort with infant leukemia. Since these subjects
would be more likely to have poor outcomes and be
CMV seronegative [6], this may have altered the
risk associated with D-/R- grafts. Most importantly,
the small number of subjects is a limitation of both
of these analyses.
In summary, we were not able to replicate the
findings in the study by Behrendt et al. Because of
the unexpected findings in their study, the larger
implications on donor matching, and the relative lack
of data in children, an assessment of larger longitudinal
datasets such as the CIBMTR or EBMT is warranted.
We believe that current recommendations to use
CMV seronegative grafts for pediatric seronegative
recipients should not be abandoned until further
studies can confirm or refute these findings.ACKNOWLEDGMENTS
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